BMEA · Biomea Fusion, Inc.

Summary

Biomea Fusion, Inc. reported financial results for the full year ended December 31, 2025, with a net loss attributable to common stockholders of $61.8 million and cash, cash equivalents, and restricted cash of $56.2 million, projecting a cash runway into the first quarter of 2027. The company highlighted clinical progress including 52-week data from COVALENT-111 and initiations of COVALENT-211, COVALENT-212, and GLP-131 trials.

Key takeaways

• Net loss attributable to common stockholders of $61.8 million for year ended December 31, 2025, compared to $138.4 million in 2024
• Cash, cash equivalents, and restricted cash of $56.2 million as of December 31, 2025, with runway into Q1 2027
• 1.2% mean HbA1c reduction maintained through Week 52 in insulin-deficient type 2 diabetes patients from COVALENT-111
• Initiated Phase II COVALENT-211 and COVALENT-212 trials for icovamenib in type 2 diabetes, 26-week topline data Q4 2026
• 52-week follow-up data from Phase II COVALENT-112 in type 1 diabetes expected Q2 2026
• Initial 28-day weight reduction data from Phase I GLP-131 for BMF-650 expected Q2 2026